

LISTING OF THE CLAIMS:

This listing of claims will replace all prior versions, and listings, of claims in the application:

1. (Previously Presented) An isolated antibody comprising a variable heavy (VH) domain having an amino acid sequence of SEQ ID NO:48, wherein said antibody immunospecifically binds to a respiratory syncytial virus (RSV) F protein.
2. (Canceled)
3. (Previously Presented) An isolated antibody comprising a variable light (VL) domain having an amino acid sequence of SEQ ID NO:20, wherein said antibody immunospecifically binds to a RSV F protein.
4. (Canceled)
5. (Previously Presented) The antibody of claim 3 further comprising a VH domain having an amino acid sequence of SEQ ID NO:48.
- 6.-178. (Canceled)
179. (Previously Presented) An isolated antibody comprising a complementarity determining region (CDR) having an amino acid sequence of a VH CDR of the antibody A4B4, wherein said antibody immunospecifically binds to a RSV F protein.
180. (Previously Presented) An isolated antibody comprising a VH CDR1 having an amino acid sequence of SEQ ID NO:10, wherein said antibody immunospecifically binds to a RSV F protein.
181. (Previously Presented) An isolated antibody comprising a VH CDR2 having an amino acid sequence of SEQ ID NO:18, wherein said antibody immunospecifically binds to a RSV F protein.
182. (Previously Presented) An isolated antibody comprising a VH CDR3 having an amino acid sequence of SEQ ID NO:19, wherein said antibody immunospecifically binds to a RSV F protein.
183. (Previously Presented) An isolated antibody comprising a VL CDR1 having an amino acid sequence of SEQ ID NO:21, wherein said antibody immunospecifically binds to a RSV F protein.

184. (Previously Presented) An isolated antibody comprising a VL CDR2 having an amino acid sequence of SEQ ID NO:22, wherein said antibody immunospecifically binds to a RSV F protein.
185. (Canceled)
186. (Previously Presented) The antibody of claim 180, wherein the antibody further comprises a VH CDR2 having an amino acid sequence of SEQ ID NO:18.
187. (Previously Presented) The antibody of claim 180, wherein the antibody further comprises a VH CDR3 having an amino acid sequence of SEQ ID NO:19.
188. (Canceled)
189. (Previously Presented) The antibody of claim 181, wherein the antibody further comprises a VH CDR3 having an amino acid sequence of SEQ ID NO:19.
- 190.-191. (Canceled)
192. (Previously Presented) The antibody of claim 183, wherein the antibody further comprises a VL CDR2 having an amino acid sequence of SEQ ID NO:22.
193. (Previously Presented) The antibody of claim 183, wherein the antibody further comprises a VL CDR3 having an amino acid sequence of SEQ ID NO: 6.
194. (Canceled)
195. (Previously Presented) The antibody of claim 184, wherein the antibody further comprises a VL CDR3 having an amino acid sequence of SEQ ID NO: 6.
- 196.-200. (Canceled)
201. (Previously Presented) The antibody of claim 183, wherein the antibody further comprises a VL CDR2 having an amino acid sequence of SEQ ID NO:22 and a VL CDR3 having an amino acid sequence of SEQ ID NO: 6.
- 202.-203. (Canceled)

204. (Previously Presented) The antibody of claim 180, wherein the antibody further comprises a VL CDR1 having an amino acid sequence of SEQ ID NO:21.
205. (Previously Presented) The antibody of claim 180, wherein the antibody further comprises a VL CDR2 having an amino acid sequence of SEQ ID NO:22.
206. (Previously Presented) The antibody of claim 180, wherein the antibody further comprises a VL CDR3 having an amino acid sequence of SEQ ID NO: 6.
207. (Previously Presented) The antibody of claim 181, wherein the antibody further comprises a VL CDR1 having an amino acid sequence of SEQ ID NO:21.
208. (Previously Presented) The antibody of claim 181, wherein the antibody further comprises a VL CDR2 having an amino acid sequence of SEQ ID NO:22.
209. (Previously Presented) The antibody of claim 181, wherein the antibody further comprises a VL CDR3 having an amino acid sequence of SEQ ID NO: 6.
210. (Previously Presented) The antibody of claim 182, wherein the antibody further comprises a VL CDR1 having an amino acid sequence of SEQ ID NO:21.
211. (Previously Presented) The antibody of claim 182, wherein the antibody further comprises a VL CDR2 having an amino acid sequence of SEQ ID NO:22.
212. (Previously Presented) The antibody of claim 182, wherein the antibody further comprises a VL CDR3 having an amino acid sequence of SEQ ID NO: 6.
- 213.-221. (Canceled)
222. (Previously Presented) The antibody of claim 186, wherein the antibody further comprises a VL CDR1 having an amino acid sequence of SEQ ID NO:21.

223. (Previously Presented) The antibody of claim 186, wherein the antibody further comprises a VL CDR2 having an amino acid sequence of SEQ ID NO:22.
224. (Previously Presented) The antibody of claim 186, wherein the antibody further comprises a VL CDR3 having an amino acid sequence of SEQ ID NO: 6.
225. (Previously Presented) The antibody of claim 187, wherein the antibody further comprises a VL CDR1 having an amino acid sequence of SEQ ID NO:21.
226. (Previously Presented) The antibody of claim 187, wherein the antibody further comprises a VL CDR2 having an amino acid sequence of SEQ ID NO:22.
227. (Previously Presented) The antibody of claim 187, wherein the antibody further comprises a VL CDR3 having an amino acid sequence of SEQ ID NO: 6.
- 228.-230. (Canceled)
231. (Previously Presented) The antibody of claim 189, wherein the antibody further comprises a VL CDR1 having an amino acid sequence of SEQ ID NO:21.
232. (Previously Presented) The antibody of claim 189, wherein the antibody further comprises a VL CDR2 having an amino acid sequence of SEQ ID NO:22.
233. (Previously Presented) The antibody of claim 189, wherein the antibody further comprises a VL CDR3 having an amino acid sequence of SEQ ID NO: 6.
- 234-240. (Canceled)
241. (Previously Presented) The antibody of claim 222, wherein the antibody further comprises a VL CDR2 having an amino acid sequence of SEQ ID NO:22.
242. (Previously Presented) The antibody of claim 223, wherein antibody further comprises a VL CDR3 having an amino acid sequence of SEQ ID NO: 6.
243. (Canceled).

244. (Previously Presented) The antibody of claim 225, wherein the antibody further comprises a VL CDR2 having an amino acid sequence of SEQ ID NO:22.
245. (Previously Presented) The antibody of claim 226, wherein antibody further comprises a VL CDR3 having an amino acid sequence of SEQ ID NO: 6.
- 246-249. (Canceled)
250. (Previously Presented) The antibody of claim 231, wherein the antibody further comprises a VL CDR2 having an amino acid sequence of SEQ ID NO:22.
- 251-279. (Canceled)
280. (Previously Presented) The antibody of claim 1, 3, 179, 180, 181, 182, 183, or 184, wherein the antibody is a monoclonal antibody.
281. (Previously Presented) The antibody of claim 1, 3, 179, 180, 181, 182, 183, or 184, wherein the antibody is a human antibody.
282. (Previously Presented) The antibody of claim 1, 3, 179, 180, 181, 182, 183, or 184, wherein the antibody is a humanized antibody.
283. (Previously Presented) The antibody of claim 1, 3, 179, 180, 181, 182, 183, or 184, wherein the antibody is a Fab fragment.
284. (Previously Presented) The antibody of claim 1, 3, 179, 180, 181, 182, 183, or 184, wherein the antibody is conjugated to a therapeutic or drug moiety.
285. (Previously Presented) The antibody of claim 1, 3, 179, 180, 181, 182, 183, or 184, wherein the antibody is conjugated to a detectable substance.
286. (Currently Amended) A pharmaceutical composition comprising the ~~The~~ antibody of claim 1, 3, 179, 180, 181, 182, 183, or 184 and a pharmaceutically acceptable carrier or excipient.
287. (Currently Amended) A kit comprising the ~~The~~ antibody of claim 1, 3, 179, 180, 181, 182, 183, or 184, in one or more containers, and instructions for use, ~~in one or more containers~~.
288. (Previously Presented) The antibody of claim 192, wherein the antibody further comprises a VH CDR1 having an amino acid sequence of SEQ ID NO:10.

289. (Previously Presented) The antibody of claim 193, wherein the antibody further comprises a VH CDR1 having an amino acid sequence of SEQ ID NO:10.
290. (Previously Presented) The antibody of claim 195, wherein the antibody further comprises a VH CDR1 having an amino acid sequence of SEQ ID NO:10.
291. (Previously Presented) The antibody of claim 201, wherein the antibody further comprises a VH CDR1 having an amino acid sequence of SEQ ID NO:10.
292. (Previously Presented) The antibody of claim 192, wherein the antibody further comprises a VH CDR2 having an amino acid sequence of SEQ ID NO:18.
293. (Previously Presented) The antibody of claim 193, wherein the antibody further comprises a VH CDR2 having an amino acid sequence of SEQ ID NO:18.
294. (Previously Presented) The antibody of claim 195, wherein the antibody further comprises a VH CDR2 having an amino acid sequence of SEQ ID NO:18.
295. (Previously Presented) The antibody of claim 201, wherein the antibody further comprises a VH CDR2 having an amino acid sequence of SEQ ID NO:18.
296. (Previously Presented) The antibody of claim 192, wherein the antibody further comprises a VH CDR3 having an amino acid sequence of SEQ ID NO:19.
297. (Previously Presented) The antibody of claim 193, wherein the antibody further comprises a VH CDR3 having an amino acid sequence of SEQ ID NO:19.
298. (Previously Presented) The antibody of claim 195, wherein the antibody further comprises a VH CDR3 having an amino acid sequence of SEQ ID NO:19.

299. (Previously Presented) The antibody of claim 201, wherein the antibody further comprises a VH CDR3 having an amino acid sequence of SEQ ID NO:19.
- 300.-302. (Canceled)
303. (Previously Presented) The antibody of claim 187, wherein the antibody further comprises a VL CDR1 having an amino acid sequence of SEQ ID NO:21 and a VL CDR3 having an amino acid sequence of SEQ ID NO:6.
304. (Canceled)
305. (Previously Presented) The antibody of claim 187, wherein the antibody further comprises a VL CDR1 having an amino acid sequence of SEQ ID NO:21, a VL CDR2 having an amino acid sequence of SEQ ID NO:22, and a VL CDR3 having an amino acid sequence of SEQ ID NO:6.
306. (Previously Presented) The antibody of claim 189, wherein the antibody further comprises a VL CDR1 having an amino acid sequence of SEQ ID NO:21 and a VL CDR3 having an amino acid sequence of SEQ ID NO:6.
307. (Previously Presented) The antibody of claim 189, wherein the antibody further comprises a VL CDR1 having an amino acid sequence of SEQ ID NO:21, a VL CDR2 having an amino acid sequence of SEQ ID NO:22, and a VL CDR3 having an amino acid sequence of SEQ ID NO:6.
308. (Previously Presented) An isolated antibody comprising a CDR having an amino acid sequence of a VL CDR1 or a VL CDR2 of the antibody P12F2, wherein said antibody immuno specifically binds to a RSV F protein.
309. (New) The antibody of claim 186, wherein the antibody further comprises a VH CDR3 having an amino acid sequence of SEQ ID NO: 19.
310. (New) The antibody of claim 309, wherein the antibody further comprises a VL CDR1 having an amino acid sequence of SEQ ID NO: 21.
311. (New) The antibody of claim 309, wherein the antibody further comprises a VL CDR2 having an amino acid sequence of SEQ ID NO:22.

- 312. (New) The antibody of claim 309, wherein the antibody further comprises a VL CDR3 having an amino acid sequence of SEQ ID NO:6.
- 313. (New) The antibody of claim 310, wherein the antibody further comprises a VL CDR2 having an amino acid sequence of SEQ ID NO:22.
- 314. (New) The antibody of claim 310, wherein the antibody further comprises a VL CDR3 having an amino acid sequence of SEQ ID NO:6.
- 315. (New) The antibody of claim 311, wherein the antibody further comprises a VL CDR3 having an amino acid sequence of SEQ ID NO:6.
- 316. (New) The antibody of claim 313, wherein the antibody further comprises a VL CDR3 having an amino acid sequence of SEQ ID NO:6.
- 317. (New) The antibody of claim 222, wherein the antibody further comprises a VL CDR3 having an amino acid sequence of SEQ ID NO:6.
- 318. (New) The antibody of claim 241, wherein the antibody further comprises a VL CDR3 having an amino acid sequence of SEQ ID NO:6.
- 319. (New) The antibody of claim 232, wherein the antibody comprises a VL CDR3 having an amino acid sequence of SEQ ID NO:6.
- 320. (New) The pharmaceutical composition of claim 286 formulated for pulmonary, intranasal or parenteral administration.
- 321. (New) The pharmaceutical composition of claim 286 which is a sustained release formulation.
- 322. (New) A lyophilized formulation comprising the antibody of claim 1, 3, 179, 180, 181, 182, 183 or 184.
- 323. (New) A liquid formulation comprising the antibody of claim 1, 3, 179, 180, 181, 182, 183 or 184.